Chimeric antigen receptor T cell (CAR-T) therapy is still challenging in targeting solid malignancies. The quality of CAR-T cell products, including T-cell memory signatures and exhaustion-related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results